UBS Group’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History

UBS Group’s Portfolio LABD Stock Details LABD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$94K	Buy	+12,195	New	+$164K	﹤0.01%	7224
2026 Q1	–	Sell	-751	Closed	-$15.8K	–	10868
2025 Q4	$15.8K	Buy	+751	New	+$20.4K	﹤0.01%	7946
2025 Q1	–	Sell	-7	Closed	-$508	–	10500
2024 Q4	$508	Sell	7 -2,239	-100%	-$137K	﹤0.01%	9443
2024 Q3	$131K	Buy	2,246 +1,436	+177%	+$87.2K	﹤0.01%	6165
2024 Q2	$59.4K	Sell	810 -1,412	-64%	-$119K	﹤0.01%	6555
2024 Q1	$162K	Sell	2,222 -987	-31%	-$82.4K	﹤0.01%	5990
2023 Q4	$311K	Buy	3,209 +3,204	+64,080%	+$623K	﹤0.01%	5469
2023 Q3	$1.09K	Sell	5 -2,465	-100%	-$400K	﹤0.01%	8109
2023 Q2	$355K	Buy	2,470 +1,541	+166%	+$230K	﹤0.01%	5094
2023 Q1	$191K	Buy	929 +28	+3%	+$4.76K	﹤0.01%	5413
2022 Q4	$155K	Sell	901 -903	-50%	-$185K	﹤0.01%	5695
2022 Q3	$432K	Buy	1,804 +947	+111%	+$220K	﹤0.01%	4469
2022 Q2	$333K	Sell	857 -2,314	-73%	-$1.16M	﹤0.01%	4567
2022 Q1	$1.11M	Buy	3,171 +3,050	+2,521%	+$1.2M	﹤0.01%	3983
2021 Q4	$31K	Sell	121 -215	-64%	-$49.4K	﹤0.01%	7363
2021 Q3	$72K	Sell	336 -782	-70%	-$166K	﹤0.01%	6069
2021 Q2	$216K	Buy	1,118 +1,111	+15,871%	+$249K	﹤0.01%	5283
2021 Q1	$1K	Buy	7 +5	+250%	+$969	﹤0.01%	8781
2020 Q4	$1K	Buy	+2	New	+$763	﹤0.01%	8227
2020 Q2	–	Hold	0	–	-$1K	–	8165
2020 Q1	–	Hold	0	–	–	–	7771
2019 Q4	–	Sell	-15	Closed	-$76K	–	8279
2019 Q3	$76K	Buy	15 +7	+88%	+$28.8K	﹤0.01%	5931
2019 Q2	$29K	Hold	8	–	–	﹤0.01%	6358
2019 Q1	$31K	Buy	+8	New	+$38.7K	﹤0.01%	5915
2018 Q4	–	Sell	-15	Closed	-$75K	–	8171
2018 Q3	$75K	Buy	+15	New	+$72.4K	﹤0.01%	5828
2018 Q2	–	Sell	-2	Closed	-$15K	–	8125
2018 Q1	$15K	Buy	+2	New	+$13.9K	﹤0.01%	6614
2017 Q3	–	Sell	-2	Closed	-$34K	–	7868
2017 Q2	$34K	Buy	+2	New	+$38.4K	﹤0.01%	5926
2017 Q1	–	Sell	-1	Closed	-$56K	–	7808
2016 Q4	$56K	Hold	1	–	–	﹤0.01%	5732
2016 Q3	$38K	Hold	1	–	–	﹤0.01%	5730
2016 Q2	$60K	Buy	+1	New	+$80.6K	﹤0.01%	5380
2016 Q1	–	Sell	-1	Closed	-$39K	–	7921
2015 Q4	$39K	Hold	1	–	–	﹤0.01%	6057
2015 Q3	$71K	Buy	+1	New	+$70.8K	﹤0.01%	5503

Other funds holding LABD

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Jump Financial Chicago, Illinois $12.4B AUM 62.79% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

UBS Group's LABD Position: Q2 2026 in Review

UBS Group opened a new position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) in Q2 2026: 12,195 shares worth $94K. The stake represents ﹤0.01% of the portfolio and ranks #7224 among its holdings. This is a return to the name: UBS Group previously reported a position in LABD as recently as Q4 2025.

UBS Group first reported a position in LABD in Q3 2015 and has held it in 30 quarters since. The position peaked at $1.11M in Q1 2022. 21 funds tracked by Wall St. Rank hold LABD as of Q2 2026.

UBS Group held 12,195 shares of Direxion Daily S&P Biotech Bear 3X ETF worth $94K as of Q2 2026.
Direxion Daily S&P Biotech Bear 3X ETF was a new UBS Group position in Q2 2026.
Direxion Daily S&P Biotech Bear 3X ETF made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7224 holding.
UBS Group first reported a position in Direxion Daily S&P Biotech Bear 3X ETF in Q3 2015 and has held it in 30 quarters since.
UBS Group's Direxion Daily S&P Biotech Bear 3X ETF position peaked at $1.11M in Q1 2022.
21 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.